We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture (ALLOB-TF2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04432389
Recruitment Status : Recruiting
First Posted : June 16, 2020
Last Update Posted : June 7, 2021
ICON plc
Information provided by (Responsible Party):
Bone Therapeutics S.A

Brief Summary:

Although the majority of tibial fractures heal normally, some fractures may not heal within the usual time frame and is known as delayed bone healing within 4 to 6 months and absence of bone healing within 9 to 12 months in the most severe case of. Several factors can increase the risks of delayed healing complications like, for example, smoking, violent shocks (for example, due to a road accident) or even the type of fracture (an open fracture). The location of the fracture is also an important factor: among the bones of the arms and legs, the tibia is known for being the most at risk for complications. At tibial fracture with several risk factors could lead to delayed complications and interfere with patient daily life and reduce the quality of life.

The study drug, ALLOB®, is constituted of bone cells produced from the bone marrow of healthy adult donors. Preclinical studies have shown that ALLOB® cells are capable of forming bone and repairing fractures. When directly injected into a fracture, ALLOB® should therefore promote the healing of the fracture by re-establishing a healthy environment and stimulating bone production. To date, there is no treatment for fractures considered at risk of delayed complications. The current practice on diagnosis of complications is to wait at least 6-12 months before considering alternative interventions to promote fracture healing. The injection of ALLOB® quickly after the fracture should stimulate bone healing, reduce healing time, reduce complications, and improve the quality of life for the patient. ALLOB® has already shown preliminary evidence of effectiveness in the treatment of delayed bone healing fractures (ALLOB-DU1 clinical trial), including tibial fractures (8 patients). With this study, the Sponsor will evaluate whether ALLOB® promotes the healing of tibial fractures compared with placebo.

Condition or disease Intervention/treatment Phase
Tibial Fracture Biological: ALLOB Other: placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 178 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Phase IIb, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture
Actual Study Start Date : January 8, 2021
Estimated Primary Completion Date : July 31, 2022
Estimated Study Completion Date : March 31, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ALLOB
Single injection of ALLOB at fracture site (4 ml)
Biological: ALLOB
After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.

Placebo Comparator: placebo
Single injection of Placebo at fracture site (4 ml)
Other: placebo
Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial

Primary Outcome Measures :
  1. proportion of subjects with a radiological success at Week 12 [ Time Frame: 12 weeks ]
    A radiological success is defined as a subject with a Radiological Union Score for Tibia (RUST) above the threshold value predictive of a normal bone healing.

Secondary Outcome Measures :
  1. Proportion of subjects with radiological success at Week 16, Week 20 and Month 6 [ Time Frame: 16 weeks - 20 weeks - 6 months ]
    A radiological success is defined as a subject with a Radiological Union Score for Tibia (RUST) above the threshold value predictive of a normal bone healing.

  2. Change in Radiographic Union Score for Tibia (RUST) at Week 12, Week 16, Week 20 and Month 6 compared to baseline visit [ Time Frame: weeks 12 - 16 - 20 - 6 months ]
    Radiological fracture healing is defined by a radiological fracture union evaluated and adjudicated by Independent Radiologists.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women at least 18 years of age
  2. Subject diagnosed with a fresh proximal, midshaft or distal tibial fracture with definitive reduction performed with nail(s) and wound closure within 1 week of fracture occurrence
  3. Mechanism of injury at risk of DU/NU: fracture occurring because of a high energy impact
  4. At increased risk of DU/NU defined by:

    • Severe open fracture (Gustilo-Anderson grade IIIa and IIIb) OR
    • Open (Gustilo-Anderson grade I-II) or closed (Tscherne grade II-III) fracture with at least one additional risk factor among smoking , comminuted fracture or cortical continuity (0-50%)
  5. Ability to obtain a written, dated, and signed informed consent prior to any study related procedures and ability to understand and comply with study requirements

Exclusion Criteria:

  1. Definitive reduction at the fracture site under investigation performed with plate, screw or external fixator
  2. Subjects who did not receive a standard antibiotic prophylaxis before definitive reduction at the fracture site under investigation
  3. Intra-articular tibial pilon and/or plateau fracture at the site under investigation
  4. Known osteomyelitis at the fracture site under investigation
  5. Bone defect post-definitive reduction greater than 1cm at least on 2 cortices at the fracture site under investigation
  6. Fracture requiring vascular surgery at the site under investigation
  7. Pathological fractures as judged by the Investigator, such as tumor or metabolic bone disease
  8. Bifocal or multifocal fracture at the site under investigation
  9. Presence of fever (defined as body temperature ≥ 38°C) or other signs/symptoms suggestive of active infection before randomization
  10. Severe brain trauma with a Glasgow Coma Scale (GCS) [3 - 8] or severe spinal cord injury with impossibility of weight-bearing
  11. Current or history (within 5 years) of any neoplasia (except for basal cell carcinoma of the skin and for carcinoma in situ of the cervix that has been treated with no evidence of recurrence)
  12. Known metabolic diseases potentially interfering with bone healing as judged by the Investigator, such as thyroid dysfunction, Paget disease or severe osteoporosis
  13. Planned or history of solid organ transplantation or bone marrow transplantation
  14. Known disease, including genetic disease, that may possibly need solid organ transplantation
  15. Subject with renal impairment requiring dialysis or with clinically significant renal impairment defined as serum creatinine >2.0 x ULN
  16. Clinically significant hepatic function impairment defined as ALT/AST levels > 3x ULN or total bilirubin levels > 2 x ULN
  17. Known hematologic disease as evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet values < 100,000/ul without another explanation
  18. Subject with an history of long standing poorly controlled chronic hypertension or diabetes that could put him at risk of needing a kidney transplant later on according to the Investigator
  19. History of hypersensitivity to human biological material including blood and blood derived products
  20. Known allergy to DMSO, dextran, gentamicin and any other aminoglycosides
  21. Participation in another interventional clinical study within 3 months prior to screening
  22. Any chronic intake of medication within one month that might affect bone metabolism or the quality of bone formation such as but not limited to bisphosphonates, teriparatide, systemic steroids, anticoagulant therapies, methotrexate and other immunosuppressant drugs or related immunotherapy
  23. Previous (within 10 years) treatment with bisphosphonates
  24. Current treatment with bone morphogenic protein or any other osteo-biologic intervention at the site of the tibial fracture

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04432389

Layout table for location contacts
Contact: Olivier Godeaux, MD +32 (0)71 121000 clinicaltrials@bonetherapeutics.com

Show Show 39 study locations
Sponsors and Collaborators
Bone Therapeutics S.A
ICON plc
Layout table for additonal information
Responsible Party: Bone Therapeutics S.A
ClinicalTrials.gov Identifier: NCT04432389    
Other Study ID Numbers: 000013/BT
First Posted: June 16, 2020    Key Record Dates
Last Update Posted: June 7, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Bone
Tibial Fractures
Wounds and Injuries
Leg Injuries